Suzanne recently described a new technique of axillary lymphadenectomy in breast cancer to reduce post surgical morbidity. It combines liposuction and endoscopic dissection. To determine whether this technique induces lymph node alterations, we examined retrospectively 111 lymphadenectomies done by this new method and compared them to 41 lymphadenectomies performed by conventional surgery.
View Article and Find Full Text PDFPurpose: A series of 53 patients with poor-prognosis epithelial ovarian cancer treated with high-dose chemotherapy (HDC) followed by hematopoietic rescue was retrospectively studied from the day of diagnosis for toxicity and long-term survival analysis.
Patients And Methods: Patients were treated with surgery followed by cisplatin combination chemotherapy. After second-look operation (SLO), HDC was administered: 23 patients received melphalan (140 mg/m2 on day 1) and 30 patients received a combination of carboplatin (400 mg/m2 on days 1 to 4) and cyclophosphamide (1.
In breast cancer treatment axillary lymphadenectomy remains essential and necessary because of its role in prognosis and in treatment. Lymphatic nodal involvement is the most important finding for prognosis and indicates the necessity of adjuvant chemotherapy. Axillary lymphadenectomy decreases the risk of local and/or regional recurrence, but it does not modify the survival rate.
View Article and Find Full Text PDF